# Clinical Study to Investigate the Efficacy of Orally Administered SA001 in Patients With Primary Sjögren's Syndrome

> **NCT05269810** · PHASE2 · COMPLETED · sponsor: **Samjin Pharmaceutical Co., Ltd.** · enrollment: 28 (actual)

## Conditions studied

- Primary Sjögren's Syndrome (pSS)

## Interventions

- **DRUG:** SA001 Low dose
- **DRUG:** SA001 Mid dose
- **DRUG:** SA001 High dose
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05269810
- **Lead sponsor:** Samjin Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-29
- **Primary completion:** 2022-02-25
- **Final completion:** 2022-03-21
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2023-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05269810

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05269810, "Clinical Study to Investigate the Efficacy of Orally Administered SA001 in Patients With Primary Sjögren's Syndrome". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05269810. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*